Trial Profile
A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adenocarcinoma; Carcinoma; Clear cell sarcoma; Endometrial cancer; Sarcoma; Squamous cell cancer
- Focus Therapeutic Use
- 28 Mar 2023 Planned End Date changed from 14 Mar 2023 to 14 Mar 2024.
- 28 Mar 2023 Planned End Date changed from 14 Mar 2023 to 14 Mar 2024.
- 28 Jan 2020 Results assessing relevance of the MET/Hepatocyte Growth Factor (HGF) pathway in endometrial cancer tumor biology supports the clinical evaluation of cabozantinib in this disease, published in the Clinical Cancer Research